Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013151627 - METHODS OF TREATING GLUCOSE METABOLISM DISORDERS

Publication Number WO/2013/151627
Publication Date 10.10.2013
International Application No. PCT/US2013/026879
International Filing Date 20.02.2013
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Applicants
  • NGM BIOPHARMACEUTICALS, INC. [US]/[US]
  • KAPLAN, Daniel, David [US]/[US]
  • SABERI, Maziyar [US]/[US]
  • ZHANG, Beilin [CN]/[US]
Inventors
  • KAPLAN, Daniel, David
  • SABERI, Maziyar
  • ZHANG, Beilin
Agents
  • BORDEN, Paula, A.
Priority Data
61/603,12924.02.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING GLUCOSE METABOLISM DISORDERS
(FR) PROCÉDÉS DE TRAITEMENT DE TROUBLES DU MÉTABOLISME DU GLUCOSE
Abstract
(EN)
Methods of treating individuals with a glucose metabolism disorder, and compositions suitable for use in the methods, are provided. As described in the disclosure, peptide subsequences derived from the Tor2a gene product have been identified. More particularly, ten murine peptides (ms p1-ms p10) and ten human peptides (hu p1-hu p10) have been identified (see Figure 2), and these peptides are distinct from the salusin peptides (i.e., neither the murine peptides nor the human peptides overlap with the murine and human amino acid sequences of the salusin peptides.
(FR)
L'invention concerne des procédés de traitement d'individus atteints d'un trouble du métabolisme du glucose et des compositions appropriées pour une utilisation dans les procédés. Des sous-séquences peptidiques dérivées du produit génétique Tor2a ont été identifiées. Plus précisément, dix peptides murins (ms p1-ms p10) et dix peptides humains (hu p1-hu p10) ont été identifiés (Figure 2) et ces peptides sont différents des peptides salusines (c'est à dire que ni les peptides murins ni les peptides humains ne chevauchent les séquences d'acides aminés murines et humaines des peptides salusines).
Latest bibliographic data on file with the International Bureau